trending Market Intelligence /marketintelligence/en/news-insights/trending/bTWmF4ebqmx207B_omR8mw2 content esgSubNav
In This List

Dr. Reddy's launches generic of Medicines Co.'s anti-coagulant in US

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Dr. Reddy's launches generic of Medicines Co.'s anti-coagulant in US

Dr. Reddy's Laboratories Ltd. launched its bivalirudin for injection, 250 milligrams/vial, in the U.S.

The drug is a generic version of the Medicines Co.'s Angiomax. Dr. Reddy's generic bivalirudin for injection was approved by the U.S. Food and Drug Administration in May.

Angiomax is a direct thrombin inhibitor indicated for use as an anti-coagulant in patients. The Angiomax brand and generic had U.S. sales of about $198 million moving annual total for the year ending March 2017, according to IMS Health data.